Tesaro, Inc.
http://tesarobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tesaro, Inc.
$500m-Plus Pours Into China Bioventures In A Week
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.
'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
GSK Keeps Oncology 2.0 Growth Plans On Track
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
GSK Cancer R&D Chief Sees Three Key Approvals In Q2
GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.